Haldol

Haldol is the brand name for haloperidol, a typical antipsychotic medication available in oral dosage forms in the European Union. The product contains the active ingredient haloperidol; specific strength and formulation details are not provided here. Haloperidol belongs to the butyrophenone class and works as a dopamine D2 receptor antagonist, used under prescription for certain psychiatric conditions. It is classified under ATC code N05AD01 and is prescribed by healthcare professionals.

Haloperidol (Haldol) is indicated for several psychiatric and neurological conditions where dopamine dysregulation is a factor. These indications reflect the drug’s dopamine‑blocking activity and its role in controlling psychomotor symptoms.

- Schizophrenia, including acute exacerbations and maintenance therapy for chronic disease. - Acute psychotic episodes not limited to schizophrenia, such as drug‑induced or brief psychotic disorder. - Manic phases of bipolar disorder, particularly when rapid symptom control is needed. - Tourette syndrome and other tic disorders, especially when tics are severe or disabling. - Severe agitation or aggression that requires prompt calming in an inpatient or emergency setting.

Haloperidol may cause a range of side effects that vary in frequency and severity.

Common: - Drowsiness or sedation, which may affect alertness during daily activities. - Extrapyramidal symptoms such as tremor, muscle rigidity, or akathisia (inner restlessness). - Dry mouth and constipation, reflecting anticholinergic activity. - Blurred vision or dizziness, especially when standing up quickly. - Weight gain or changes in appetite, which can occur over weeks of treatment.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening reaction characterized by high fever, muscle rigidity, and autonomic instability. - Tardive dyskinesia, characterized by involuntary facial or limb movements that may persist after discontinuation. - Significant cardiac arrhythmias, including QT interval prolongation that can increase the risk of sudden cardiac events.

When prescribing haloperidol, clinicians consider several precautions to minimize risks and ensure safe use.

- Assess for a history of cardiovascular disease, as haloperidol may affect heart rhythm. - Monitor for signs of extrapyramidal symptoms, especially in patients with Parkinsonian features. - Use caution in elderly patients, who may be more susceptible to sedation and falls. - Evaluate liver and kidney function before initiating therapy, adjusting dose if impairment is present. - Screen for a personal or family history of neuroleptic malignant syndrome. - Consider pregnancy and breastfeeding status; safety data are limited.

Haloperidol can interact with other medicines, affecting its efficacy or increasing the risk of adverse effects. These interactions may necessitate dose adjustments or closer clinical observation.

Avoid: - Concurrent use with other dopamine antagonists, such as other antipsychotics or antiemetics, may intensify extrapyramidal side effects and increase motor impairment. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) can raise haloperidol plasma concentrations, heightening the risk of toxicity.

Use with caution: - CNS depressants such as benzodiazepines, barbiturates, or opioids may increase sedation and impair psychomotor performance. - Anticholinergic agents (e.g., benztropine, trihexyphenidyl) can mask early signs of extrapyramidal symptoms, making monitoring more difficult. - Medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics, may increase the likelihood of cardiac arrhythmias and require ECG monitoring.